Background: Intracranial neoplasms can cause pain similar to trigeminal neuralgia. Literature regarding radiosurgery for this is limited. We present a retrospective review of patients with tumor-related facial pain from benign lesions treated with gamma knife radiosurgery (GKRS) at Wake Forest University. Objectives: The primary objectives were to determine long-term pain relief and predictive factors for pain alleviation. Methods: We reviewed 515 patients treated with GKRS for benign meningioma, vestibular schwannoma or trigeminal schwannoma between August 1999 and August 2010. Twenty-one eligible patients had tumor-related facial pain prior to GKRS. The median marginal tumor dose was 12 Gy. Long-term pain relief data were obtained by chart review and telephone interview. Results: The median follow-up for symptom evaluation was 3.8 years. Seventeen of 21 patients (81%) experienced a Barrow Neurological Institute (BNI) score of I–III at 6 months following GKRS. Kaplan-Meier estimates of freedom from BNI IV–V relapse were 66% at 1 year and 53% at 2 years. No pain relapses occurred after 2 years. Conclusion: GKRS of benign lesions is a noninvasive option for patients with tumor-related facial pain. Pain relief is modest, with the majority of pain relapses occurring within 2 years and approximately one half of patients maintaining relief beyond 2 years.

1.
Bullitt E, Tew JM, Boyd J: Intracranial tumors in patients with facial pain. J Neurosurg 1986;64:865–871.
2.
Nomura T, Ikezaki K, Matsushima T, Fukui M: Trigeminal neuralgia: differentiation between intracranial mass lesions and ordinary vascular compression as causative lesions. Neurosurg Rev 1994;17:51–57.
3.
Miller JP, Acar F, Burchiel KJ: Trigeminal neuralgia and vascular compression in patients with trigeminal schwannomas: case report. Neurosurgery 2008;62:E974–E975, discussion E975.
4.
Kondziolka D, Mathieu D, Lunsford LD, Martin JJ, Madhok R, Niranjan A, Flickinger JC: Radiosurgery as definitive management of intracranial meningiomas. Neurosurgery 2008;62:53–58, discussion 58–60.
5.
Flickinger JC, Kondziolka D, Niranjan A, Maitz A, Voynov G, Lunsford LD: Acoustic neuroma radiosurgery with marginal tumor doses of 12 to 13 Gy. Int J Radiat Oncol Biol Phys 2004;60:225–230.
6.
Chopra R, Kondziolka D, Niranjan A, Lunsford LD, Flickinger JC: Long-term follow-up of acoustic schwannoma radiosurgery with marginal tumor doses of 12 to 13 Gy. Int J Radiat Oncol Biol Phys 2007;68:845–851.
7.
Hasegawa T, Kida Y, Yoshimoto M, Koike J: Trigeminal schwannomas: results of gamma knife surgery in 37 cases. J Neurosurg 2007;106:18–23.
8.
Sakamoto GT, Borchers DJ 3rd, Xiao F, Yang HJ, Chang SD, Adler JR Jr: Cyberknife radiosurgery for trigeminal schwannomas. Neurosurgery 2009;64:A14–A18.
9.
Spiegelmann R, Cohen ZR, Nissim O, Alezra D, Pfeffer R: Cavernous sinus meningiomas: a large LINAC radiosurgery series. J Neurooncol 2010;98:195–202.
10.
Regis J, Metellus P, Dufour H, Roche PH, Muracciole X, Pellet W, Grisoli F, Peragut JC: Long-term outcome after gamma knife surgery for secondary trigeminal neuralgia. J Neurosurg 2001;95:199–205.
11.
Huang CF, Tu HT, Liu WS, Lin LY: Gamma knife surgery for trigeminal pain caused by benign brain tumors. J Neurosurg 2008;109(suppl):154–159.
12.
Pollock BE, Iuliano BA, Foote RL, Gorman DA: Stereotactic radiosurgery for tumor-related trigeminal pain. Neurosurgery 2000;46:576–582, discussion 582–573.
13.
Burchiel KJ: A new classification for facial pain. Neurosurgery 2003;53:1164–1166, discussion 1166–1167.
14.
Kondziolka D, Zorro O, Lobato-Polo J, Kano H, Flannery TJ, Flickinger JC, Lunsford LD: Gamma knife stereotactic radiosurgery for idiopathic trigeminal neuralgia. J Neurosurg 2010;112:758–765.
15.
Young RF, Vermeulen SS, Grimm P, Blasko J, Posewitz A: Gamma knife radiosurgery for treatment of trigeminal neuralgia: idiopathic and tumor related. Neurology 1997;48:608–614.
16.
Riesenburger RI, Hwang SW, Schirmer CM, Zerris V, Wu JK, Mahn K, Klimo P Jr, Mignano J, Thompson CJ, Yao KC: Outcomes following single-treatment gamma knife surgery for trigeminal neuralgia with a minimum 3-year follow-up. J Neurosurg 2010;112:766–771.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.